SMC Update - January 2025
The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Ciclosporin (Cequa®) drops have been accepted for restricted use in the treatment of moderate-to-severe Dry Eye Disease (keratoconjunctivitis sicca) in adult patients who have not responded adequately to artificial tears. The restriction limits use to cases of severe keratitis in adult patients.
Relugolix, estradiol, norethisterone tablets (Ryeqo®) has been accepted for use in adult women of reproductive age for symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
| « Seroxat tablets discontinued | NICE Guidance - January 2025 » |
Leave a Comment